Key result
Proximal DNAJB6 mutations link to proximal limb-girdle myopathy and distal mutations to distal-onset myopathy.
Why the study?
The phenotypic spectrum and genotype-phenotype correlations of DNAJB6-myopathy mutations, including novel mutations and complete loss of the G/F domain, were not fully characterized.
Observational (n=9)
Yes
Expands the genotypic and phenotypic spectrum of DNAJB6 myopathy, establishing tentative genotype-phenotype correlations based on mutation location within the G/F domain.
May refine genetic counseling in DNAJB6 myopathy; leaves open validation of domain-specific phenotypes in larger cohorts.
INTRODUCTION: Protein aggregation is a common cause of neuropathology. The protein aggregation myopathy Limb-Girdle Muscular Dystrophy 1D (LGMD1D) is caused by mutations of amino acids Phe89 or Phe93 of DNAJB6, a co-chaperone of the HSP70 anti-aggregation protein. Another DNAJB6 mutation, Pro96Arg, was found to cause a distal-onset myopathy in one family. RESULTS: We detail the mutational, neuropathological, neurophysiological, neurological and radiological features of five new DNAJB6-myopathy families. One has the known Phe93Leu mutation and classic late-onset slowly progressive LGMD1D. Two have different mutations of Phe91 causing a variant childhood-onset severe limb-girdle myopathy. One has a Phe100Val mutation and distal-onset myopathy, unique early bulbar involvement, and a gender-modified wide age-of-onset range. The last has childhood-onset severe distal-onset myopathy and the first non-missense DNAJB6 mutation, c.346 + 5G > A, causing a splicing defect that entirely eliminates DNAJB6's G/F domain (ΔG/F), the domain that harbours all other mutations. Clinical and imaging examinations reveal that muscles considered uninvolved in DNAJB6-myopathy, e.g. lateral gastrocnemii, are affected in our patients with new mutations. Mutational modelling based on the known structure of the bacterial DNAJ2 protein indicates that all past and present mutated residues cluster within 15 Å in the G/F domain and all disturb the interface of this domain with the protein's J domain that confers the interaction with HSP70. CONCLUSIONS: Our patients expand the phenotypic spectrum of DNAJB6-myopathy and allow tentative genotype-phenotype specifications. Combining with previous studies, the clinical severity spectrum is as follows: ΔG/F and Phe91 mutations, most severe; Phe100, Pro96, Phe89 mutations, intermediate; and Phe93, least severe. As it stands presently, proximal G/F domain mutations (Phe89, Phe91, Phe93) cause proximal limb-girdle myopathy, while distal G/F mutations (Pro96, Phe100) cause distal-onset myopathy. While all mutations affect the G/F-J interaction, each likely does so in different unknown extents or ways. One mutation, ΔG/F, causes its associated severe distal-onset myopathy phenotype in a clear way, through generation of a G/F domain-lacking DNAJB6 protein.
No takes yet. Share an insight, caveat, or question.
Ruggieri et al. (2015) conducted an observational in DNAJB6 myopathy (n=9). DNAJB6 mutations was evaluated on Phenotypic presentation (proximal vs distal myopathy). Mutations in the proximal G/F domain of DNAJB6 cause proximal limb-girdle myopathy, whereas mutations in the distal G/F domain or complete loss of the domain cause distal-onset myopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: